{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:34:23Z","timestamp":1792197263895,"version":"4.4.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000145","name":"Alberta Innovates - Health Solutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jconrel.2019.08.018","type":"journal-article","created":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T17:43:42Z","timestamp":1566063822000},"page":"141-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers"],"prefix":"10.1016","volume":"310","author":[{"given":"Juliana","family":"Valencia-Serna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezary","family":"Kucharski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remant","family":"KC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Brandwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-4170","authenticated-orcid":false,"given":"Hasan","family":"Uluda\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2019.08.018_bb0005","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O\u2019Hare","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0010","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","article-title":"Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management","volume":"89","author":"Jabbour","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0015","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0025","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/jcmm.12873","article-title":"Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor","volume":"20","author":"Corrado","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0030","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0035","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0040","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0045","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1038\/mtna.2015.13","article-title":"Progress in RNAi-mediated molecular therapy of acute and chronic myeloid leukemia","volume":"4","author":"Landry","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0050","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1038\/sj.onc.1205653","article-title":"Killing of leukemic cells with a BCR\/ABL fusion gene by RNA interference (RNAi)","volume":"21","author":"Wilda","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0055","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jconrel.2010.04.011","article-title":"Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells","volume":"145","author":"Arthanari","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0060","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.actbio.2015.07.032","article-title":"Stealth monoolein-based nanocarriers for delivery of siRNA to cancer cells","volume":"25","author":"Oliveira","year":"2015","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0065","first-page":"55","article-title":"Nucleostemin depletion induces post-g1 arrest apoptosis in chronic myelogenous leukemia k562 cells","volume":"4","author":"Seyed-Gogani","year":"2014","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0070","doi-asserted-by":"crossref","first-page":"9405","DOI":"10.1039\/C6NR00996D","article-title":"Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR\u2013ABL hybrid oncogene in a human chronic myeloid leukemia cell line","volume":"8","author":"Yang","year":"2016","journal-title":"Nanoscale."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0075","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.bbrc.2016.03.018","article-title":"Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem\/progenitor cell function","volume":"472","author":"Xiao","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0080","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood-2002-06-1685","article-title":"Specific inhibition of bcr-abl gene expression by small interfering RNA","volume":"101","author":"Scherr","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.leu.2403999","article-title":"Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation","volume":"20","author":"Rangatia","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149919","article-title":"Novel acylguanidine derivatives targeting smoothened induce antiproliferative and pro-apoptotic effects in chronic myeloid leukemia cells","volume":"11","author":"Chiarenza","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0095","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12013-014-0434-2","article-title":"HIF-\u03b1 promotes chronic myelogenous leukemia cell proliferation by upregulating p21 expression","volume":"72","author":"Chen","year":"2015","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/bc9004365","article-title":"Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment","volume":"21","author":"Mendon\u00e7a","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0105","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jconrel.2013.05.014","article-title":"Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation","volume":"172","author":"Valencia-Serna","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0110","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/cmdc.200700329","article-title":"Targeted RNA interference of cyclin A2 mediated by functionalized single-walled carbon nanotubes induces proliferation arrest and apoptosis in chronic myelogenous leukemia K562 cells","volume":"3","author":"Wang","year":"2008","journal-title":"ChemMedChem."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/mt.2013.210","article-title":"Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability","volume":"22","author":"He","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0120","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/blood-2002-12-3899","article-title":"Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)","volume":"102","author":"Wohlbold","year":"2003","journal-title":"Blood."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0125","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor\u2013induced cell death in Philadelphia chromosome\u2013positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0130","first-page":"326","article-title":"WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells","volume":"90","author":"Elmaagacli","year":"2005","journal-title":"Haematologica."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0135","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/cgt.2013.31","article-title":"Additive antileukemia effects by GFI1B- and BCR\u2013ABL-specific siRNA in advanced phase chronic myeloid leukemic cells","volume":"20","author":"Koldehoff","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0140","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/nm1127","article-title":"Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells","volume":"10","author":"Ptasznik","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0145","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood-2010-10-313692","article-title":"Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells","volume":"118","author":"Gioia","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0150","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1756-8722-6-64","article-title":"Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation","volume":"6","author":"Shen","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0155","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1078-0432.CCR-13-3317","article-title":"Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells","volume":"21","author":"Wu","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0160","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.biomaterials.2011.11.079","article-title":"Supramolecular assemblies in functional siRNA delivery: where do we stand?","volume":"33","author":"Aliabadi","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0165","doi-asserted-by":"crossref","first-page":"9382","DOI":"10.1016\/j.biomaterials.2014.07.029","article-title":"siRNA therapy in cutaneous T-cell lymphoma cells using polymeric carriers","volume":"35","author":"\u015eahin","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044197","article-title":"Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethylenimines","volume":"7","author":"Landry","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0175","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jconrel.2015.12.052","article-title":"Targeting CXCR4\/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia","volume":"224","author":"Landry","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0180","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.leukres.2014.08.008","article-title":"Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells","volume":"38","author":"G\u00fcl-Uludag","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0185","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2217\/nnm.16.32","article-title":"Fibronectin-modified surfaces for evaluating the influence of cell adhesion on sensitivity of leukemic cells to siRNA nanoparticles","volume":"11","author":"Valencia-Serna","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0190","article-title":"BCR-Abl silencing by siRNA: a potent approach to sensitize chronic myeloid leukemia cells to TKI therapy","author":"KC","year":"2018","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejpb.2018.06.018","article-title":"siRNA\/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo","volume":"130","author":"Valencia-Serna","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0200","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/mabi.201000402","article-title":"Impact of lipid substitution on assembly and delivery of siRNA by cationic polymers","volume":"11","author":"Aliabadi","year":"2011","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0205","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1039\/C4TB02101K","article-title":"Additive nanocomplexes of cationic lipopolymers for improved non-viral gene delivery to mesenchymal stem cells","volume":"3","author":"KC","year":"2015","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0210","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1084\/jem.20072316","article-title":"AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem\/progenitor cells","volume":"205","author":"Zhou","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0215","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0220","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2002-03-0777","article-title":"The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML","volume":"100","author":"O'Dwyer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0225","doi-asserted-by":"crossref","DOI":"10.1089\/scd.2018.0196","article-title":"BCR-AblSilencing by short interfering RNA: a potent approach to sensitize chronic myeloid leukemia cells to tyrosine kinase inhibitor therapy","author":"KC","year":"2019","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2013.00031","article-title":"How cholesterol interacts with membrane proteins: an exploration of cholesterol-binding sites including CRAC, CARC, and tilted domains","volume":"4","author":"Fantini","year":"2013","journal-title":"Front. Physiol."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0235","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1126\/science.1068886","article-title":"A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains","volume":"296","author":"Anderson","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0240","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1021\/jp910077h","article-title":"Study on the interaction of cationic lipids with bovine serum albumin","volume":"114","author":"Charbonneau","year":"2009","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0245","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0022-2275(20)33379-4","article-title":"Cellular uptake and intracellular trafficking of long chain fatty acids","volume":"40","author":"McArthur","year":"1999","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0250","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11010-005-9034-1","article-title":"Translocation of long chain fatty acids across the plasma membrane \u2013 lipid rafts and fatty acid transport proteins","volume":"284","author":"Ehehalt","year":"2006","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.jconrel.2019.08.018_bb0255","doi-asserted-by":"crossref","first-page":"24822","DOI":"10.1021\/acsami.5b07929","article-title":"A delicate balance when substituting a small hydrophobe onto low molecular weight polyethylenimine to improve its nucleic acid delivery efficiency","volume":"7","author":"Menekseda\u011f-Erol","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0260","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1016\/j.biomaterials.2007.07.023","article-title":"A comparative evaluation of poly-l-lysine-palmitic acid and Lipofectamine \u2122 2000 for plasmid delivery to bone marrow stromal cells","volume":"28","author":"Clements","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0265","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0270","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1182\/blood-2013-07-516807","article-title":"The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem\/progenitor cells","volume":"123","author":"Rothe","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2019.08.018_bb0275","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1186\/s13045-017-0470-7","article-title":"Current status and perspectives of patient-derived xenograft models in cancer research","volume":"10","author":"Lai","year":"2017","journal-title":"J. Hematol. Oncol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919304985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919304985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:42:54Z","timestamp":1759160574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365919304985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":55,"alternative-id":["S0168365919304985"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.08.018","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}